US 12,427,148 B2
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
Davide Ruggero, Emerald Hill, CA (US); Hao Nguyen, San Francisco, CA (US); Peter Carroll, San Francisco, CA (US); and Crystal Conn, Oakland, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jan. 14, 2022, as Appl. No. 17/576,623.
Application 17/576,623 is a continuation of application No. 16/396,723, filed on Apr. 28, 2019, granted, now 11,253,522.
Claims priority of provisional application 62/664,144, filed on Apr. 28, 2018.
Prior Publication US 2022/0152035 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 35/02 (2006.01); G01N 33/573 (2006.01); G01N 33/574 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 35/02 (2018.01); G01N 33/573 (2013.01); G01N 33/57434 (2013.01); A61K 45/06 (2013.01); G01N 2440/14 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of treating cancer in a subject,
comprising the steps of:
obtaining a sample comprising cancerous cells from the subject;
assessing PTEN loss in the cancerous cells;
assessing Myc activation in the cancerous cells; and
wherein, if both PTEN loss and Myc activation in the cancerous cells is observed, administering to the subject a pharmaceutically active amount of an agent which inhibits the PERK-mediated integrated stress response, wherein the cancerous cells of the subject comprise breast cancer cells.